SELLAS Life Sciences Group (SLS) Reached A Phase 3 REGAL Milestone, Is The Stock A Bargain?

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets

SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS

SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400%

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?

SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?

Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%

SELLAS Life Sciences Shares Drop 18% After REGAL Leukemia Trial Hits 80th Death, Triggering Final Analysis

Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final Data

10 Health Care Stocks Whale Activity In Today’s Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)